New EU HTA guideline tackles thorny issue of comparators
This article was originally published in Scrip
Executive Summary
Companies and interest groups frustrated by Germany's tough new approach to relative benefit assessments of new drugs may be heartened, if only moderately, by the publication of draft guidance on how to choose the most appropriate comparator.